| SIU School of Medicine

News

Ebru Demir, MSc, PhD: Exploring the brain’s blueprint for connection

SIU research scientist Ebru Demir studies how the brain forms, values and remembers human relationships — and what happens when that process breaks down.

News

Ebru Demir, MSc, PhD: Exploring the brain’s blueprint for connection

SIU research scientist Ebru Demir studies how the brain forms, values and remembers human relationships — and what happens when that process breaks down.

General Results

NIH guidance

Recent NIH policy updates Early Stage Investigator (ESI) eligibility NIH has issued a short-term extension to the ESI eligibility period to accommodate disruptions in research progress. NOT-OD-25-114 NRSA childcare cost clarification Updated procedures clarify how institutions can request and manage childcare costs for NRSA institutional training awards. (NOT-OD-25-100) Public Access Policy - effective date moved up The revised NIH Public Access Policy will now take effect on July 1, 2025, earlier than initially announced. (NOT-OD-25-101) Biological research safety guidance NIH has released

General Results

Corrections Connection

Corrections Connection is a dedicated job board designed for Illinois corrections and public safety employers—connecting you directly with qualified candidates who are ready to serve. Whether you're hiring correctional officers, nurses, counselors, administrators or parole staff, our platform gives you the tools to post, manage and fill positions with ease. Post your openings to reach a highly targeted audience of corrections professionals and track engagement in real time—completely free. Learn more in the videos below.

Trial

Psychiatry

ITI-007-601: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Lumateperone in the Treatment of Irritability Associated with Autism Spectrum Disorder in Pediatric Patients 5 to 17 Years of Age

Active recruiting

The primary objective is to evaluate the efficacy of high and low doses of lumateperone vs placebo for the

Trial

Neurology

Xenon XPF-010-303: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

Active recruiting

The primary objective is to assess the effect of XEN1101 versus placebo on reducing PGTCS frequency in subj

Trial

Neurology

Xenon XPF-010-302: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

Active recruiting

The primary objective of this study is to assess the effect of XEN1101 versus placebo on reducing focal sei

Trial

Neurology

UCB EP0165: An Open-Label, Multicenter, Outpatient Extension Study to Evaluate the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting

The primary endpoint of this study is to evaluate the long-term safety and tolerability of Staccato alprazo

Trial

Neurology

UCB EP0162: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older with Stereotypical Prolonged Seizures

Active recruiting

The purpose of this study is to compare the success of a single admnistration of Staccato alprazolam compar

Trial

Neurology

Supernus Renaissance 2: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of SPN-817 in Adults with Focal Onset Seizures

Active recruiting

To evaluate the efficacy of SPN-817 as a treatment for adult participants with focal onset seizures.